Search...
Sinobioway Medicine has been subjected to other risk warnings, and its stock abbreviation has been changed to "ST Sinobioway"
I'm PortAI, I can summarize articles.
Sinobioway Medicine's controlling subsidiary, Tianjin Sinobioway Biomedicine Co., Ltd., is expected to be unable to resume normal production. Starting from July 8, 2025, the stock will be subject to "other risk warnings," and its abbreviation will be changed to "ST Sinobioway." After a one-day suspension, it will resume trading with a daily price fluctuation limit reduced from 10% to 5%
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments